Pharmaceutical CEOs use earnings calls to criticize drug-pricing proposal
August 05, 2022 at 07:29 AM EDT
Executives at AbbVie, J&J, and Merck say the suggested changes in their current form would be 'chilling' or 'detrimental' to the development of new therapies.
